November 25, 2020

Glenmark Pharma cuts worth of COVID-19 drug by 27% to Rs 75 per pill



New Delhi: Drug agency Glenmark Prescribed drugs on Monday stated it has discount of its antiviral drug Favipiravir, beneath the model identify FabiFlu, for the therapy of sufferers with delicate to average COVID-19, by 27 per cent to Rs 75 per pill. Glenmark Prescribed drugs had launched FabiFlu final month at a worth of Rs 103 per pill.

In a regulatory submitting Glenmark introduced a worth discount of 27 per cent for FabiFlu. The brand new most retail worth (MRP) is Rs 75 per tab, it stated.

“The value discount has been made potential by means of advantages gained from greater yields and higher scale, as each the lively pharmaceutical ingredient (API) and formulations are made at Glenmark’s services in India, the advantages of that are being handed on to sufferers within the nation,” the submitting stated.

“Our inner analysis exhibits us that we launched FabiFlu in India on the lowest market value as in comparison with the price of Favipiravir in different nations the place it’s authorized. And now we hope that this additional worth discount will make it much more accessible for sufferers throughout the nation,” Glenmark Prescribed drugs Senior Vice President and Head – India enterprise Alok Malik stated.

Additional, the corporate has commenced a submit advertising surveillance (PMS) research on FabiFlu to intently monitor the efficacy and security of the drug in 1,000 sufferers which might be prescribed with the oral antiviral, as a part of an open label, multicenter, single arm research, the submitting added.

“We count on this submit advertising surveillance research to shed extra mild on the drug’s scientific effectiveness and security in a big cohort of sufferers prescribed FabiFlu,” Malik added.

On June 20, Glenmark introduced that it acquired manufacturing and advertising approval from India’s drug regulator for FabiFlu, making it the primary oral Favipiravir-approved treatment in India for the therapy of delicate to average COVID-19.

Glenmark has additionally accomplished the section three scientific trial with Favipiravir (FabiFlu) in delicate to average COVID-19 sufferers in India. The trial outcomes shall be accessible shortly, the corporate stated.

Glenmark can be conducting one other section three scientific trial to judge the efficacy of two antivirals medicine Favipiravir and Umifenovir as a mix remedy in average hospitalised grownup COVID-19 sufferers in India.

Shares of Glenmark Pharma have been buying and selling 1.34 per cent decrease at Rs 421.00 apiece on BSE.